Fig 1.
(A) standard care without dose adjustments, (B) tapering, (C) withdrawal, (D) tapering followed by withdrawal of bDMARDs. REM: remission, LDA: low disease activity, M/HDA: medium to high disease activity, TP_REM: remission under tapering, TP_LDA: low disease activity under tapering, WD_REM: remission under immediate withdrawal, WD_LDA: low disease activity under immediate withdrawal. Arrows indicate possible transitions between states at each model cycle of 6 months.
Table 1.
Transition probabilities.
Table 2.
Base case model parameters, upper and lower bounds for deterministic sensitivity analysis and distribution parameters for probabilistic sensitivity analysis.
Fig 2.
Results of deterministic sensitivity analyses for incremental costs and quality-adjusted life years (QALYs).
Fig 3.
Results of Monte Carlo simulations depicted in incremental-cost-effectiveness-ratio (ICER) planes and cost-effectiveness-acceptability curves (CEAC).
Table 3.
Results from scenario and structural sensitivity analyses.